Patents by Inventor Agnes M. Rimando

Agnes M. Rimando has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190059368
    Abstract: Analogs of stilbene, and in particular, 3,5-dimethoxystilbene, are disclosed. Also disclosed are various uses for the different compounds described. The uses of the disclosed 3,5-dimethoxystilbene analogs include treatment as a pesticide, nematicide, fungicide, bactericide, and antimicrobial agent. Many of the analogs are novel, and procedures for synthesis are also provided.
    Type: Application
    Filed: August 7, 2018
    Publication date: February 28, 2019
    Inventors: AGNES M. RIMANDO, JIAN-QUAN WENG
  • Patent number: 9439875
    Abstract: We report for the first time that pterostilbene, a natural analog of resveratrol, shows anxiolytic-like action by downregulating phosphorylated levels of ERKs in the hippocampus of mice. Mice administered pterostilbene (1-10 mg/kg BW) by oral gavage were subjected to the Elevated-plus maze (EPM) test. Pterostilbene manifested anxiolytic activity at 1 and 2 mg/kg doses, demonstrated by an increase in percent permanence time and number of entries in open arms, critical determinants correlated with anxiety. This anxiolytic activity of pterostilbene was comparable to that of diazepam at 1 and 2 mg/kg in the EPM. The percent traveled distance and the percent permanence time in the enclosed arms were decreased with the 1 and 2 mg/kg doses. The 5 and 10 mg/kg doses did not show any anxiolytic effect. Locomotor activity was unaffected in all doses.
    Type: Grant
    Filed: May 11, 2011
    Date of Patent: September 13, 2016
    Assignees: The United States of America, as represented by The Secretary of Agriculture, University of Mississippi
    Inventors: Agnes M. Rimando, Abir El-Alfy, Md Al Rahim
  • Publication number: 20160067192
    Abstract: We report for the first time that pterostilbene, a natural analog of resveratrol, shows anxiolytic-like action by downregulating phosphorylated levels of ERKs in the hippocampus of mice. Mice administered pterostilbene (1-10 mg/kg BW) by oral gavage were subjected to the Elevated-plus maze (EPM) test. Pterostilbene manifested anxiolytic activity at 1 and 2 mg/kg doses, demonstrated by an increase in percent permanence time and number of entries in open arms, critical determinants correlated with anxiety. This anxiolytic activity of pterostilbene was comparable to that of diazepam at 1 and 2 mg/kg in the EPM. The percent traveled distance and the percent permanence time in the enclosed arms were decreased with the 1 and 2 mg/kg doses. The 5 and 10 mg/kg doses did not show any anxiolytic effect. Locomotor activity was unaffected in all doses.
    Type: Application
    Filed: May 11, 2011
    Publication date: March 10, 2016
    Inventors: Agnes M. Rimando, Abir El-Alfy, Md Al Rahim
  • Patent number: 9248145
    Abstract: Sorghum is considered an allelopathic crop species and sorgoleone likely accounts for much of its allelopathic properties. Prior investigations into the biosynthesis of sorgoleone suggested the participation of one or more alkylresorcinol synthases (ARS), which are type III polyketide synthases (PKS) that produce 5-alkylresorcinols using medium to long-chain fatty acyl-CoA starter units via iterative condensations with malonyl-CoA. Quantitative real-time RT-PCR analysis of PKS-like sequences mined from isolated root hairs revealed that two sequences, designated ARS1 and ARS2, were preferentially expressed. Recombinant enzyme studies demonstrated that both sequences encode ARS enzymes capable of accepting a variety of fatty acyl-CoA starter units. RNA interference (RNAi) experiments directed against ARS1 and ARS2 resulted in the generation of multiple independent transformant events exhibiting dramatically reduced sorgoleone levels.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: February 2, 2016
    Assignee: The United States of America, as represented by The Secretary of Agriculture
    Inventors: Scott R. Baerson, Zhiqiang Pan, Agnes M. Rimando, Franck E. Dayan, Daniel Cook
  • Patent number: 9028887
    Abstract: Disclosed is a pharmaceutical composition for treating oxidative stress comprising a therapeutically effective amount of a substantially pure compound of pterostilbene and a physiologically acceptable carrier. Pterostilbene is administered in an amount between about 2.5 mg to about 10 mg per kilogram of subject body weight. Also disclosed is a method for increasing a working memory of a subject, the method comprising administrating an effective amount of a substantially pure compound of pterostilbene, wherein the working memory for a subject increase and the therapeutic effectiveness is about 10 mg of pterostilbene per kilogram of subject body weight.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: May 12, 2015
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: James A. Joseph, Agnes M. Rimando, Barbara Shukitt-Hale
  • Publication number: 20140256827
    Abstract: Disclosed is a pharmaceutical composition for treating oxidative stress comprising a therapeutically effective amount of a substantially pure compound of pterostilbene and a physiologically acceptable carrier. Pterostilbene is administered in an amount between about 2.5 mg to about 10 mg per kilogram of subject body weight. Also disclosed is a method for increasing a working memory of a subject, the method comprising administrating an effective amount of a substantially pure compound of pterostilbene, wherein the working memory for a subject increase and the therapeutic effectiveness is about 10 mg of pterostilbene per kilogram of subject body weight.
    Type: Application
    Filed: May 22, 2014
    Publication date: September 11, 2014
    Inventors: James A. Joseph, Agnes M. Rimando, Barbara Shukitt-Hale
  • Patent number: 8809400
    Abstract: Disclosed is a pharmaceutical composition for treating oxidative stress comprising a therapeutically effective amount of a substantially pure compound of pterostilbene and a physiologically acceptable carrier. Pterostilbene is administered in an amount between about 2.5 mg to about 10 mg per kilogram of subject body weight. Also disclosed is a method for increasing a working memory of a subject, the method comprising administrating an effective amount of a substantially pure compound of pterostilbene, wherein the working memory for a subject increase and the therapeutic effectiveness is about 10 mg of pterostilbene per kilogram of subject body weight.
    Type: Grant
    Filed: August 8, 2011
    Date of Patent: August 19, 2014
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: James A. Joseph, Agnes M. Rimando, Barbara Shukitt-Hale
  • Patent number: 8426369
    Abstract: Stilbene compounds for the prevention and treatment of colon cancer or colon inflammation and methods of using same are provided.
    Type: Grant
    Filed: December 7, 2007
    Date of Patent: April 23, 2013
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Agnes M. Rimando, Nanjoo Suh, Cassia Suemi Mizuno, Subhashini Reddy
  • Patent number: 8383890
    Abstract: This invention relates to the fatty acid desaturase genes, designated SbDES2 and SbDES3, cloned from an expressed sequence tag (EST) database prepared from isolated root hairs from sorghum. Heterologous expression of the cDNAs in S. cerevisiae revealed that recombinant SbDES2 converted palmitoleic acid (16:1?9) to hexadecadienoic acid (16:2?9, 12), and that recombinant SbDES3 was capable of converting hexadecadienoic acid into hexadecatrienoic acid (16:3?9, 12, 15). Desaturase enzymes capable of performing desaturation reactions producing a terminal double bond have not previously been characterized in a plant system.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: February 26, 2013
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Zhiqiang Pan, Agnes M. Rimando, Scott R. Baerson
  • Patent number: 8252845
    Abstract: Resveratrol has been reported to have hypolipidemic properties. We investigated whether resveratrol and its analogs: pterostilbene, piceatannol and resveratrol trimethyl ether, would activate the peroxisome proliferator-activated receptor alpha (PPAR?) isoform. This nuclear receptor is proposed to mediate the activity of lipid-lowering drugs such as the fibrates. The four stilbenes and ciprofibrate (positive control) were evaluated for the activation of endogenous PPAR? in H4IIEC3 cells transfected with a luciferase gene reporter construct. Pterostilbene demonstrated the highest induction of PPAR?; the maximal response to pterostilbene was similar to that obtained with the hypolipidemic drug, ciprofibrate.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: August 28, 2012
    Assignees: The United States of America, as represented by the Secretary of Agriculture, The University of Mississippi
    Inventors: Agnes M. Rimando, Dennis R. Feller, Wallace H. Yokoyama
  • Publication number: 20120178704
    Abstract: Stilbene compounds for the prevention and treatment of colon cancer or colon inflammation and methods of using same are provided.
    Type: Application
    Filed: December 7, 2007
    Publication date: July 12, 2012
    Inventors: Agnes M. Rimando, Nanjoo Suh, Cassia Mizuno, Bandaru s. Reddy, Sada L. Reddy
  • Patent number: 8133917
    Abstract: Resveratrol, a stilbenoid antioxidant found in grapes, wine, peanuts and other berries, has been reported to have hypolipidemic properties. Resveratrol and its three analogs (pterostilbene, piceatannol and resveratrol trimethyl ether) were evaluated for their effects on the activation of the peroxisome proliferator-activated receptor alpha (PPAR?) isoforms, a receptor shown to mediate the activity of lipid-lowering drugs such as the fibrates. The four stilbenes and ciprofibrate (positive control) were evaluated for the activation of endogenous PPAR? in H4IIEC3 cells. Pterostilbene demonstrated the highest induction of PPAR? demonstrating increases of 7- and 9-14 fold relative to control. The maximal responses to pterostilbene are similar to those obtained with the hypolipidemic drug, ciprofibrate; that is, pterostilbene acts as a PPAR? agonist, like that of the fibrate class, and is a more effective hypolipidemic agent than resveratrol.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: March 13, 2012
    Assignees: The United States of America as represented by the Secretary of Agriculture, The University of Mississippi
    Inventors: Agnes M. Rimando, Dennis R. Feller, Wallace H. Yokoyama
  • Publication number: 20120035272
    Abstract: Disclosed is a pharmaceutical composition for treating oxidative stress comprising a therapeutically effective amount of a substantially pure compound of pterostilbene and a physiologically acceptable carrier. Pterostilbene is administered in an amount between about 2.5 mg to about 10 mg per kilogram of subject body weight. Also disclosed is a method for increasing a working memory of a subject, the method comprising administrating an effective amount of a substantially pure compound of pterostilbene, wherein the working memory for a subject increase and the therapeutic effectiveness is about 10 mg of pterostilbene per kilogram of subject body weight.
    Type: Application
    Filed: August 8, 2011
    Publication date: February 9, 2012
    Applicant: The United States of America as represented by the Secretary of Agriculture
    Inventors: James A. Joseph, Agnes M. Rimando, Barbara Shukitt-Hale
  • Publication number: 20110225676
    Abstract: Sorghum is considered to be an allelopathic crop species, producing phytotoxins such as the lipid benzoquinone sorgoleone (2-hydroxy-5-methoxy-3-[(Z,Z)-8?,11?,14?-pentadecatriene]-p-benzoquinone) which likely accounts for much of its allelopathic properties. Prior investigations into the biosynthesis of sorgoleone have suggested the participation of one or more alkylresorcinol synthases (ARS), which are type III polyketide synthases (PKS) that produce 5-alkylresorcinols using medium to long-chain fatty acyl-CoA starter units via iterative condensations with malonyl-CoA. Current evidence suggests that sorgoleone biosynthesis occurs exclusively in root hair cells, involving the synthesis of a 5-pentadecatrienyl resorcinol intermediate derived from an unusual 16:3 fatty acyl-CoA starter unit.
    Type: Application
    Filed: March 10, 2010
    Publication date: September 15, 2011
    Inventors: Scott R. Baerson, Zhiqiang Pan, Agnes M. Rimando, Franck E. Dayan, Daniel Cook
  • Publication number: 20110060060
    Abstract: Resveratrol, a stilbenoid antioxidant found in grapes, wine, peanuts and other berries, has been reported to have hypolipidemic properties. Resveratrol and its three analogs (pterostilbene, piceatannol and resveratrol trimethyl ether) were evaluated for their effects on the activation of the peroxisome proliferator-activated receptor alpha (PPAR?) isoforms, a receptor shown to mediate the activity of lipid-lowering drugs such as the fibrates. The four stilbenes and ciprofibrate (positive control) were evaluated for the activation of endogenous PPAR? in H4IIEC3 cells. Pterostilbene demonstrated the highest induction of PPAR? demonstrating increases of 7- and 9-14 fold relative to control. The maximal responses to pterostilbene are similar to those obtained with the hypolipidemic drug, ciprofibrate; that is, pterostilbene acts as a PPAR? agonist, like that of the fibrate class, and is a more effective hypolipidemic agent than resveratrol.
    Type: Application
    Filed: October 25, 2010
    Publication date: March 10, 2011
    Inventors: Agnes M. Rimando, Dennis R. Feller, Wallace H. Yokoyama
  • Patent number: 7732666
    Abstract: This invention relates to an O-methyltransferase gene cloned from sorghum, the sorghum O-methyltransferase-3 gene, SbOMT3. Quantitative real-time RT-PCR and recombinant enzyme studies with putative O-methyltransferase sequences obtained from an EST data set from sorghum have led to the identification of the novel root hair-specific O-methyltransferase designated SbOMT3. Transgenic plants which express SbOMT3 can convert resveratrol into pterostilbene in planta. SbOMT3 is also involved in the biosynthesis of sorgoleone.
    Type: Grant
    Filed: September 1, 2006
    Date of Patent: June 8, 2010
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: Scott R. Baerson, Agnes M. Rimando, Franck E. Dayan, Zhiqiang Pan, James J. Polashock
  • Publication number: 20090069444
    Abstract: Disclosed is a pharmaceutical composition for treating oxidative stress comprising a therapeutically effective amount of a substantially pure compound of pterostilbene and a physiologically acceptable carrier. Pterostilbene is administered in an amount between about 2.5 mg to about 10 mg per kilogram of subject body weight. Also disclosed is a method for increasing a working memory of a subject, the method comprising administrating an effective amount of a substantially pure compound of pterostilbene, wherein the working memory for a subject increase and the therapeutic effectiveness is about 10 mg of pterostilbene per kilogram of subject body weight.
    Type: Application
    Filed: June 10, 2008
    Publication date: March 12, 2009
    Applicant: The United States of America, as represented by th e Secretary of Agriculture
    Inventors: James A. Joseph, Agnes M. Rimando, Barbara Shukitt-Hale